Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor-Alpha Production in Mice after Bone Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 4, 2016, Pages 627-636

  Liu, Jiajia ^a   Guo, Yong Mei ^a   Onai, Nobuyuki ^b,c   Ohyagi, Hideaki ^a   Hirokawa, Makoto ^a   Takahashi, Naoto ^a   Tagawa, Hiroyuki ^a   Ubukawa, Kumi ^a   Kobayashi, Isuzu ^a   Tezuka, Hiroyuki ^d   Minamiya, Yoshihiro ^a   Ohteki, Toshiaki ^b,c   Sawada, Kenichi ^e  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d HOSHI UNIVERSITY   (Japan)

^e AKITA UNIVERSITY   (Japan)

Author keywords

Bone marrow transplantation; Cytosine phosphorothionate guanine oligodeoxynucleotide (CpG ODN); Hemophagocytic syndrome; IFN ; TNF

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ETANERCEPT; INTERLEUKIN-6, MOUSE; MONOCLONAL ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHROPHAGOCYTOSIS; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; SPLEEN CELL; UPREGULATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; CPG ISLAND; CYTOLOGY; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ISOGRAFT; KNOCKOUT MOUSE; LYMPHOCYTE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CPG ISLANDS; ETANERCEPT; GAMMA RAYS; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; INTERFERON-GAMMA; INTERLEUKIN-6; LYMPHOCYTES; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; TUMOR NECROSIS FACTOR-ALPHA; WHOLE-BODY IRRADIATION;

EID: 84960472167     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.12.018     Document Type: Article

References (37)

1. Fisman D.N. Hemophagocytic syndromes and infection. Emerg Infect Dis 2000, 6:601-608.
2. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355:1018-1028.
3. Henter J.I., Horne A., Arico M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:124-131.
4. Janka G.E. Hemophagocytic syndromes. Blood Rev 2007, 21:245-253.
5. Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286:1957-1959.
6. Rouphael N.G., Talati N.J., Vaughan C., et al. Infections associated with haemophagocytic syndrome. Lancet Infect Dis 2007, 7:814-822.
7. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002, 14:548-552.
8. Lambotte O., Khellaf M., Harmouche H., et al. Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore) 2006, 85:169-182.
9. Takagi S., Masuoka K., Uchida N., et al. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol 2009, 147:543-553.
10. Dale D.C., Boxer L., Liles W.C. The phagocytes: neutrophils and monocytes. Blood 2008, 112:935-945.
11. Klinman D.M., Takeshita F., Gursel I., et al. Cpg DNA: recognition by and activation of monocytes. Microbes Infect 2002, 4:897-901.
12. Krieg A.M. CPG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
13. Krug A., Rothenfusser S., Hornung V., et al. Identification of CPG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.
14. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by cpg DNA. J Exp Med 1998, 188:2335-2342.
15. Behrens E.M., Canna S.W., Slade K., et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011, 121:2264-2277.
16. Ohyagi H., Onai N., Sato T., et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 2013, 39:584-598.
17. Grom A.A. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. Arthritis Rheum 2004, 50:689-698.
18. Mazodier K., Marin V., Novick D., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106:3483-3489.
19. Behrens E.M., Kreiger P.A., Cherian S., Cron R.Q. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006, 33:2081-2084.
20. Busca A. The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert Opin Biol Ther 2011, 11:687-697.
21. Olin R.L., Nichols K.E., Naghashpour M., et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol 2008, 83:747-749.
22. Prahalad S., Bove K.E., Dickens D., et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001, 28:2120-2124.
23. Spitalny G.L., Havell E.A. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med 1984, 159:1560-1565.
24. Taniguchi T., Takata M., Ikeda A., et al. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor alpha-deficient mice. Lab Invest 1997, 77:647-658.
25. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
26. Liu R., Bal H.S., Desta T., et al. Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 2006, 168:757-764.
27. Jordan M.B., Hildeman D., Kappler J., Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104:735-743.
28. Imahashi N., Inamoto Y., Ito M., et al. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012, 47:387-394.
29. Hill G.R., Crawford J.M., Cooke K.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90:3204-3213.
30. Pachlopnik Schmid J., Cote M., Menager M.M., et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010, 235:10-23.
31. Taylor P.A., Ehrhardt M.J., Lees C.J., et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 2008, 112:3508-3516.
32. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
33. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
34. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
35. Piguet P.F., Grau G.E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987, 166:1280-1289.
36. Henzan T., Nagafuji K., Tsukamoto H., et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 2006, 81:59-61.
37. Makay B., Yilmaz S., Turkyilmaz Z., et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer 2008, 50:419-421.